SCHEMBL12907457

SCHEMBL12907457

Cc1n[nH]c2cc(-c3ccc(-c4ccccc4)cc3)ccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.67
CHEK1 O14757 6/20 0.56
AXL P30530 1/20 0.55
MKNK1 Q9BUB5 1/20 0.53
PDPK1 O15530 4/20 0.51
CDK4 P11802 2/20 0.51
CCNA2 P20248 2/20 0.51
CCND1 P24385 2/20 0.51
CDK2 P24941 2/20 0.51
CCND3 P30281 2/20 0.51
CDK1 P06493 1/20 0.51
GSK3B P49841 2/20 0.51
FGFR1 P11362 2/20 0.50
TNKS2 Q9H2K2 1/20 0.50
TTK P33981 1/20 0.50
KDR P35968 1/20 0.50
GSK3A P49840 1/20 0.49
FGFR2 P21802 1/20 0.49
FGFR3 P22607 1/20 0.49
AURKA O14965 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907469 0.88 JAK2 (0.53) JAK2CHEK1AXLMKNK1PDPK1
SCHEMBL14397096 0.87 PDPK1 (0.53) JAK2CHEK1AXLPDPK1CDK4
SCHEMBL27968550 0.86 MKNK1 (0.71) JAK2CHEK1AXLMKNK1CDK4
SCHEMBL12907451 0.84 FGFR1 (0.70) JAK2CHEK1PDPK1CDK2GSK3B
SCHEMBL12907435 0.83 CHEK1 (0.58) JAK2CHEK1PDPK1CDK4CCNA2
SCHEMBL12907471 0.82 AAK1 (0.57) JAK2PDPK1GSK3BFGFR1FGFR2
SCHEMBL1513016 0.81 FGFR1 (0.71) JAK2CHEK1AXLMKNK1PDPK1
SCHEMBL12907438 0.81 GSK3B (0.54) JAK2CHEK1PDPK1CDK4CCNA2
SCHEMBL12907468 0.81 GSK3B (0.54) JAK2CHEK1PDPK1CDK4CCNA2
SCHEMBL12907422 0.80 GSK3B (0.55) JAK2CHEK1PDPK1CDK4CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed